Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Voriconazole
Drug ID BADD_D02369
Description Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections.[L15571] It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increased affinity of voriconazole for 14-alpha sterol demethylase makes it useful against some [fluconazole]-resistant organisms.[A236050] Voriconazole was approved by the FDA under the trade name Vfend on May 24, 2002.[L34660]
Indications and Usage For the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp.
Marketing Status Prescription
ATC Code J02AC03
DrugBank ID DB00582
KEGG ID D00578
MeSH ID D065819
PubChem ID 71616
TTD Drug ID D0N3VR
NDC Product Code 0904-6596; 0049-3180; 40032-089; 70966-0030; 65841-831; 43547-378; 0049-4190; 0904-6471; 0781-5668; 0395-8230; 27241-062; 72266-131; 68462-573; 70710-1247; 51552-1524; 0378-1640; 60715-1700; 0781-5667; 40032-038; 65862-891; 60687-294; 43547-377; 43386-088; 51407-133; 53296-0081; 63629-8734; 43386-089; 0049-3170; 65862-916; 65841-830; 66039-951; 60687-273; 59762-0935; 70771-1413; 0049-3190; 58032-2007; 0378-1626; 14501-0014; 63739-008; 68462-572; 16436-0081; 72969-077; 51079-165; 27241-063; 64980-274; 65015-801; 51552-1573; 52562-001; 72578-063; 0904-7024; 65862-892; 63126-911; 65219-190; 72578-062; 0781-3416; 70436-029; 64220-140; 59762-0936; 16714-199; 68083-321; 65372-1175; 51079-164; 59762-0934; 43386-038; 64980-275; 66039-876; 39822-1077; 0049-3160; 68554-0111; 40032-088; 71052-149; 65162-913; 47781-466; 73223-005; 16714-198; 55111-099
Synonyms Voriconazole | UK 109,496 | UK-109,496 | UK109,496 | UK-109496 | UK109496 | UK 109496 | Vfend
Chemical Information
Molecular Formula C16H14F3N5O
CAS Registry Number 188416-29-7
SMILES CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.003--
Abnormal dreams19.02.03.001; 17.15.02.0010.066556%Not Available
Accommodation disorder06.02.04.001--Not Available
Actinic keratosis23.01.06.0010.279535%Not Available
Acute hepatic failure09.01.03.0010.041670%Not Available
Acute leukaemia16.01.02.001; 01.10.02.0010.010417%Not Available
Acute lymphocytic leukaemia01.10.01.001; 16.01.01.0010.010417%Not Available
Acute myeloid leukaemia16.01.05.001; 01.10.05.0010.079867%Not Available
Acute respiratory distress syndrome22.01.03.001--
Adrenal insufficiency14.11.01.004; 05.01.02.0010.026622%
Ageusia17.02.07.001; 07.14.03.003--Not Available
Agitation19.06.02.001; 17.02.05.0120.199668%
Agranulocytosis01.02.03.0010.226290%Not Available
Akathisia19.06.02.006; 17.01.02.002--
Alanine aminotransferase increased13.03.01.0030.199668%
Albuminuria20.02.01.001--Not Available
Alopecia23.02.02.001--
Altered state of consciousness19.07.01.003; 17.02.04.0010.412647%Not Available
Amaurosis06.02.02.0080.026622%Not Available
Amnesia19.20.01.001; 17.03.02.001--
Anaemia01.03.02.001--
Anaemia macrocytic14.12.01.002; 01.03.02.002--Not Available
Anaemia megaloblastic14.12.01.003; 01.03.02.003--Not Available
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Angioedema23.04.01.001; 10.01.05.009--Not Available
Anorectal disorder07.03.01.001--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 22 Pages